{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.90","estimateComment":"Hazard ratio (HR) \\< 1 favours the cabazitaxel group and \\> 1 favours the mitoxantrone group.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0010","paramType":"Cox Proportional Hazard","paramValue":"0.75","statisticalComment":"Log-rank comparisons stratified according to disease measurability and ECOG performance status.","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"4.4","value":"3.1"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"7.3","value":"6.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"377"},{"groupId":"OG001","value":"378"}],"units":"Participants"}],"description":"In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later.\n\nIn PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later.","dispersionType":"95% Confidence Interval","groups":[{"description":"mitoxantrone 12 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG000","title":"Mitoxantrone + Prednisone"},{"description":"cabazitaxel 25 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG001","title":"Cabazitaxel + Prednisone"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on the intention To Treat (ITT) population. The ITT population is composed of all randomized patients (i.e. patients assigned to a treatment group by the randomization, regardless of whether patients received any study drug or received a different study drug from which they were randomized).","reportingStatus":"POSTED","timeFrame":"at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)","title":"Time to Prostatic Specific Antigen (PSA) Progression","type":"SECONDARY","unitOfMeasure":"Months"}